This trial will test a new drug for people who had weight-loss surgery. The drug is taken twice daily, and the trial will evaluate how well it works and if it is safe.
- Post-Gastric Bypass Surgery
1 Primary · 4 Secondary · Reporting Duration: Screening, Days 1, 15, and 28
Awards & Highlights
1 Treatment Group
1 of 1
12 Total Participants · 1 Treatment Group
Primary Treatment: ARD-101 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 75 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is the application window for this trial still available?
"Affirmative. According to the information displayed on clinicaltrials.gov, this medical trial is actively seeking participants and has been since March 1st 2022. The last update was made October 18th of that same year and so far 30 people have enrolled from a single site." - Anonymous Online Contributor
Does the demographic of 65+ apply to this research investigation?
"This medical study has established an age limit between 18 and 75 years old for participants, as specified in the inclusion criteria." - Anonymous Online Contributor
What are the criteria to be a participant in this research trial?
"This trial is currently recruiting 30 individuals with a BMI between 35-60 kg/m2 and ages ranging from 18 to 75. To be eligible, one must meet the following criteria: Male or female subjects aged 18-75 years old; they have undergone sleeve gastrectomy surgery at least 12 months ago and regained 20% of their nadir weight loss (defined as maximum preoperative weight - weight corresponding to a BMI of 25 kg/m2); serum creatinine, alkaline phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase) and" - Anonymous Online Contributor
What is the total participant count for this experiment?
"Affirmative. Information on clinicaltrials.gov indicates that this research project is presently accepting enrolment, having been first posted on March 1st 2022 and most recently modified October 18th 2022. 30 individuals are sought after from a single site for the trial." - Anonymous Online Contributor
Has the U.S. Food and Drug Administration given their stamp of approval for ARD-101?
"Our analysts at Power assigned ARD-101 a score of 2 on the safety scale as it is currently in its second trial phase, meaning there are some data backing up security but no evidence confirming efficacy." - Anonymous Online Contributor